Header Logo

Connection

HASHEM EL-SERAG to Liver Neoplasms

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Liver Neoplasms.
HASHEM EL-SERAG
Connection Strength
25.966
Liver Neoplasms
  1. HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. J Hepatol. 2026 Mar; 84(3):578-586.
    View in: PubMed
    Score: 0.446
  2. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 04; 61(7):1226-1237.
    View in: PubMed
    Score: 0.426
  3. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.416
  4. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2025 Feb 01; 81(2):465-475.
    View in: PubMed
    Score: 0.407
  5. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.404
  6. Race/ethnicity and sex differences in the association between area-level arsenic exposure concentration and hepatocellular carcinoma (HCC) incidence rates in Texas. An ecological study. Environ Res. 2024 Jan 01; 240(Pt 2):117538.
    View in: PubMed
    Score: 0.390
  7. Opportunities to address gaps in early detection and improve outcomes of liver cancer. JNCI Cancer Spectr. 2023 05 02; 7(3).
    View in: PubMed
    Score: 0.377
  8. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.377
  9. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
    View in: PubMed
    Score: 0.376
  10. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.372
  11. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.371
  12. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2023 02; 43(1):89-99.
    View in: PubMed
    Score: 0.362
  13. Recent Decline in the Incidence of Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2023 08; 21(9):2418-2420.e3.
    View in: PubMed
    Score: 0.358
  14. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
    View in: PubMed
    Score: 0.348
  15. The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4.
    View in: PubMed
    Score: 0.346
  16. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 01; 73 Suppl 1:4-13.
    View in: PubMed
    Score: 0.318
  17. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2021 07; 19(7):1443-1450.e6.
    View in: PubMed
    Score: 0.312
  18. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. J Gastroenterol Hepatol. 2020 Oct; 35(10):1684-1693.
    View in: PubMed
    Score: 0.307
  19. Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Dig Dis Sci. 2021 03; 66(3):912-916.
    View in: PubMed
    Score: 0.305
  20. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
    View in: PubMed
    Score: 0.304
  21. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
    View in: PubMed
    Score: 0.302
  22. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2020 05; 158(6):1822-1830.
    View in: PubMed
    Score: 0.301
  23. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.291
  24. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr Gastroenterol Rep. 2019 Apr 11; 21(4):17.
    View in: PubMed
    Score: 0.284
  25. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
    View in: PubMed
    Score: 0.282
  26. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol. 2019 09; 17(10):2117-2125.e3.
    View in: PubMed
    Score: 0.279
  27. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1886-1893.e5.
    View in: PubMed
    Score: 0.278
  28. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019 01; 156(2):477-491.e1.
    View in: PubMed
    Score: 0.275
  29. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.272
  30. Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology. 2018 07; 68(1):7-9.
    View in: PubMed
    Score: 0.267
  31. How we approach it: treatment options for hepatocellular carcinoma. Am J Gastroenterol. 2018 06; 113(6):791-794.
    View in: PubMed
    Score: 0.266
  32. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat. 2018 05; 25(5):543-551.
    View in: PubMed
    Score: 0.265
  33. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1.
    View in: PubMed
    Score: 0.260
  34. The treatment path in hepatocellular carcinoma. Clin Adv Hematol Oncol. 2017 Aug; 15 Suppl 9(8):1-20.
    View in: PubMed
    Score: 0.253
  35. Advances in the management of hepatocellular carcinoma. Clin Adv Hematol Oncol. 2017 Aug; 15 Suppl 9(8):2-6.
    View in: PubMed
    Score: 0.253
  36. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017 Jul-Sep; 24(3):1073274817729245.
    View in: PubMed
    Score: 0.251
  37. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.251
  38. Hepatocellular carcinoma surveillance: The road ahead. Hepatology. 2017 03; 65(3):771-773.
    View in: PubMed
    Score: 0.244
  39. ?Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study. Ann Hepatol. 2017 Jan-Feb 2017; 16(1):16-20.
    View in: PubMed
    Score: 0.243
  40. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017 03; 152(4):812-820.e5.
    View in: PubMed
    Score: 0.241
  41. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016 12; 65(6):1148-1154.
    View in: PubMed
    Score: 0.236
  42. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.231
  43. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology. 2015 Dec; 149(7):1986-7.
    View in: PubMed
    Score: 0.224
  44. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015 Nov; 13(12):2140-51.
    View in: PubMed
    Score: 0.221
  45. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014 Nov; 60(5):1767-75.
    View in: PubMed
    Score: 0.206
  46. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014 Sep; 109(9):1427-35.
    View in: PubMed
    Score: 0.205
  47. Obesity and hepatocellular carcinoma: hype and reality. Hepatology. 2014 Sep; 60(3):779-81.
    View in: PubMed
    Score: 0.204
  48. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
    View in: PubMed
    Score: 0.203
  49. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May; 146(5):1249-55.e1.
    View in: PubMed
    Score: 0.198
  50. Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Rev Gastroenterol Hepatol. 2013 Aug; 7(6):493-5.
    View in: PubMed
    Score: 0.192
  51. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013 Nov; 58(11):3117-26.
    View in: PubMed
    Score: 0.191
  52. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013 Jul; 47 Suppl:S2-6.
    View in: PubMed
    Score: 0.191
  53. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013 May; 57(5):1858-68.
    View in: PubMed
    Score: 0.187
  54. a-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):441-3.
    View in: PubMed
    Score: 0.185
  55. Surveillance for hepatocellular carcinoma: long way to achieve effectiveness. Dig Dis Sci. 2012 Dec; 57(12):3050-1.
    View in: PubMed
    Score: 0.181
  56. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1342-1359.e2.
    View in: PubMed
    Score: 0.181
  57. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May; 142(6):1264-1273.e1.
    View in: PubMed
    Score: 0.176
  58. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol. 2012 Jan; 46(1):71-7.
    View in: PubMed
    Score: 0.172
  59. Hepatocellular carcinoma. N Engl J Med. 2011 Sep 22; 365(12):1118-27.
    View in: PubMed
    Score: 0.168
  60. Level of a-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011 Nov; 9(11):989-94.
    View in: PubMed
    Score: 0.167
  61. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011 Jul; 60(7):992-7.
    View in: PubMed
    Score: 0.161
  62. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
    View in: PubMed
    Score: 0.161
  63. Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology. 2011 Mar; 53(3):1060-1; author reply 1061-2.
    View in: PubMed
    Score: 0.160
  64. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr; 140(4):1182-1188.e1.
    View in: PubMed
    Score: 0.160
  65. Surveillance for hepatocellular carcinoma: development and validation of an algorithm to classify tests in administrative and laboratory data. Dig Dis Sci. 2010 Nov; 55(11):3241-51.
    View in: PubMed
    Score: 0.157
  66. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010 Jul; 42 Suppl 3:S206-14.
    View in: PubMed
    Score: 0.155
  67. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010 Jul; 52(1):132-41.
    View in: PubMed
    Score: 0.155
  68. Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2009 Jun; 55(2):123-38.
    View in: PubMed
    Score: 0.144
  69. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009 May; 136(5):1601-8.
    View in: PubMed
    Score: 0.140
  70. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology. 2009 Jan; 49(1):116-23.
    View in: PubMed
    Score: 0.140
  71. Hepatocellular cancer care: cost is important but only one factor of disease burden. J Hepatol. 2009 Jan; 50(1):10-2.
    View in: PubMed
    Score: 0.138
  72. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008 May; 134(6):1752-63.
    View in: PubMed
    Score: 0.133
  73. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol. 2008 Feb 15; 167(4):377-89.
    View in: PubMed
    Score: 0.130
  74. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med. 2007 Oct 08; 167(18):1983-9.
    View in: PubMed
    Score: 0.128
  75. Utilization of screening for hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2007 Sep; 41(8):777-82.
    View in: PubMed
    Score: 0.127
  76. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007 Jun; 132(7):2557-76.
    View in: PubMed
    Score: 0.125
  77. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007 Oct; 47(4):506-13.
    View in: PubMed
    Score: 0.124
  78. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2006 Jun; 15(6):1198-203.
    View in: PubMed
    Score: 0.117
  79. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006 Mar; 4(3):369-80.
    View in: PubMed
    Score: 0.115
  80. Validation of longitudinal biomarker screening algorithms for HCC detection in patients with cirrhosis. Hepatol Commun. 2026 Mar 01; 10(3).
    View in: PubMed
    Score: 0.114
  81. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol. 2006 Jan; 4(1):104-10; quiz 4-5.
    View in: PubMed
    Score: 0.113
  82. Evolving burden of metabolic dysfunction-associated steatotic liver disease and its complications in a US nationwide healthcare system. Hepatol Commun. 2026 Jan 01; 10(1).
    View in: PubMed
    Score: 0.113
  83. The Association Between Physical Activity, Sedentary Time, and Sleep with Risk of Hepatocellular Carcinoma in Patients with Cirrhosis. Dig Dis Sci. 2026 Apr; 71(4):1522-1529.
    View in: PubMed
    Score: 0.112
  84. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006 Jan; 44(1):158-66.
    View in: PubMed
    Score: 0.112
  85. Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits. Int J Cancer. 2026 Mar 01; 158(5):1193-1203.
    View in: PubMed
    Score: 0.111
  86. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005 Apr; 54(4):533-9.
    View in: PubMed
    Score: 0.108
  87. Management of the single liver nodule in a cirrhotic patient: a decision analysis model. J Clin Gastroenterol. 2005 Feb; 39(2):152-9.
    View in: PubMed
    Score: 0.106
  88. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005 Jan; 100(1):56-63.
    View in: PubMed
    Score: 0.106
  89. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004 Nov 22; 164(21):2349-54.
    View in: PubMed
    Score: 0.105
  90. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
    View in: PubMed
    Score: 0.105
  91. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004 Nov; 127(5 Suppl 1):S27-34.
    View in: PubMed
    Score: 0.105
  92. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004 Nov; 127(5):1372-80.
    View in: PubMed
    Score: 0.105
  93. Neighborhood-level deprivation mediates racial and ethnic disparities in HCC diagnosis in Texas. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.104
  94. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004 Mar; 39(3):798-803.
    View in: PubMed
    Score: 0.100
  95. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004 Mar; 40(3):472-7.
    View in: PubMed
    Score: 0.100
  96. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 07 01; 80(1):87-101.
    View in: PubMed
    Score: 0.100
  97. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004 Feb; 126(2):460-8.
    View in: PubMed
    Score: 0.099
  98. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003 Nov 18; 139(10):817-23.
    View in: PubMed
    Score: 0.098
  99. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003 Nov; 98(11):2535-42.
    View in: PubMed
    Score: 0.097
  100. Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol. 2003 May; 56(5):487-93.
    View in: PubMed
    Score: 0.094
  101. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023 08; 20(8):487-503.
    View in: PubMed
    Score: 0.093
  102. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.091
  103. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002 Nov-Dec; 35(5 Suppl 2):S72-8.
    View in: PubMed
    Score: 0.091
  104. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002 Nov; 36(5 Suppl 1):S74-83.
    View in: PubMed
    Score: 0.091
  105. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
    View in: PubMed
    Score: 0.090
  106. Surveillance for hepatocellular carcinoma: does it work? Am J Gastroenterol. 2002 Oct; 97(10):2676-7.
    View in: PubMed
    Score: 0.090
  107. Clinical care in hepatocellular carcinoma: A mixed methods assessment of experiences and challenges of oncology professionals. Cancer Med. 2023 02; 12(3):3670-3683.
    View in: PubMed
    Score: 0.090
  108. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2002 Sep; 35(3):266-9.
    View in: PubMed
    Score: 0.090
  109. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.090
  110. Neighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas. Clin Gastroenterol Hepatol. 2023 05; 21(5):1314-1322.e5.
    View in: PubMed
    Score: 0.089
  111. Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
    View in: PubMed
    Score: 0.089
  112. Risk of Hepatocellular Carcinoma in Patients with Various HFE Genotypes. Dig Dis Sci. 2023 01; 68(1):312-322.
    View in: PubMed
    Score: 0.089
  113. Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1402-1409.
    View in: PubMed
    Score: 0.089
  114. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.089
  115. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022 10; 19(10):638-651.
    View in: PubMed
    Score: 0.089
  116. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022 07 05; 34(7):969-977.e2.
    View in: PubMed
    Score: 0.088
  117. Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology. 2022 05; 75(5):1289-1299.
    View in: PubMed
    Score: 0.086
  118. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022 06; 75(6):1420-1428.
    View in: PubMed
    Score: 0.086
  119. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022 03; 75(3):541-549.
    View in: PubMed
    Score: 0.086
  120. Interferon: benefit beyond hepatitis therapy? Am J Gastroenterol. 2001 Dec; 96(12):3435-6.
    View in: PubMed
    Score: 0.085
  121. Rational HCC screening approaches for patients with NAFLD. J Hepatol. 2022 01; 76(1):195-201.
    View in: PubMed
    Score: 0.084
  122. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol. 2001 Aug; 96(8):2462-7.
    View in: PubMed
    Score: 0.083
  123. A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum. Clin Gastroenterol Hepatol. 2022 05; 20(5):1174-1176.
    View in: PubMed
    Score: 0.083
  124. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila). 2021 06; 14(6):667-674.
    View in: PubMed
    Score: 0.081
  125. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001 Feb; 5(1):87-107, vi.
    View in: PubMed
    Score: 0.081
  126. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control. 2021 Apr; 32(4):317-325.
    View in: PubMed
    Score: 0.080
  127. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001 Jan; 33(1):62-5.
    View in: PubMed
    Score: 0.080
  128. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021 04; 18(4):223-238.
    View in: PubMed
    Score: 0.080
  129. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000 Nov 27; 160(21):3227-30.
    View in: PubMed
    Score: 0.080
  130. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.079
  131. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 07; 66(7):2439-2451.
    View in: PubMed
    Score: 0.078
  132. Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1679-1687.
    View in: PubMed
    Score: 0.078
  133. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
    View in: PubMed
    Score: 0.074
  134. Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):88-94.
    View in: PubMed
    Score: 0.074
  135. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 2019 09 01; 79(17):4326-4330.
    View in: PubMed
    Score: 0.073
  136. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Dig Dis Sci. 2019 11; 64(11):3328-3336.
    View in: PubMed
    Score: 0.071
  137. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11; 340(10):745-50.
    View in: PubMed
    Score: 0.071
  138. Determinants and Outcomes of Hospice Utilization Among Patients with Advance-Staged Hepatocellular Carcinoma in a Veteran Affairs Population. Dig Dis Sci. 2018 05; 63(5):1173-1181.
    View in: PubMed
    Score: 0.066
  139. Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis? Aliment Pharmacol Ther. 2018 02; 47(3):437-438.
    View in: PubMed
    Score: 0.065
  140. Sleep Duration and Risk of Liver Cancer in Postmenopausal Women: The Women's Health Initiative Study. J Womens Health (Larchmt). 2017 12; 26(12):1270-1277.
    View in: PubMed
    Score: 0.064
  141. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
    View in: PubMed
    Score: 0.063
  142. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1207-1217.e4.
    View in: PubMed
    Score: 0.061
  143. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
    View in: PubMed
    Score: 0.060
  144. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat. 2016 09; 23(9):687-96.
    View in: PubMed
    Score: 0.058
  145. Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing. Med Care. 2016 Feb; 54(2):e9-14.
    View in: PubMed
    Score: 0.057
  146. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016 Mar; 43(5):621-30.
    View in: PubMed
    Score: 0.057
  147. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res. 2016 Feb; 200(2):552-9.
    View in: PubMed
    Score: 0.056
  148. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul; 149(1):119-29.
    View in: PubMed
    Score: 0.054
  149. Surveillance for hepatocellular carcinoma: can we focus on the mission? Clin Gastroenterol Hepatol. 2015 Apr; 13(4):805-7.
    View in: PubMed
    Score: 0.053
  150. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):594-601.e1.
    View in: PubMed
    Score: 0.052
  151. Response to Braillon. Am J Gastroenterol. 2013 Dec; 108(12):1931.
    View in: PubMed
    Score: 0.049
  152. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
    View in: PubMed
    Score: 0.047
  153. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013 Aug; 108(8):1314-21.
    View in: PubMed
    Score: 0.047
  154. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):428-33.
    View in: PubMed
    Score: 0.043
  155. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011 Aug; 54(2):463-71.
    View in: PubMed
    Score: 0.041
  156. Increased risk of hepatocellular carcinoma after cholecystectomy. Br J Cancer. 2011 Jun 28; 105(1):154-6.
    View in: PubMed
    Score: 0.041
  157. Hepatocellular carcinoma at the cutting edge of science and practice. Minerva Med. 2010 Dec; 101(6):391-3.
    View in: PubMed
    Score: 0.040
  158. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010 Nov; 8(11):924-33; quiz e117.
    View in: PubMed
    Score: 0.039
  159. Achieving health equity to eliminate racial, ethnic, and socioeconomic disparities in HBV- and HCV-associated liver disease. J Fam Pract. 2010 Apr; 59(4 Suppl):S37-42.
    View in: PubMed
    Score: 0.038
  160. The risk of hepatocellular carcinoma in patients with previous malignancy. Cancer Invest. 2008 Jun; 26(5):511-5.
    View in: PubMed
    Score: 0.033
  161. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol. 2008 Jan; 103(1):120-7.
    View in: PubMed
    Score: 0.032
  162. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol. 2007 Apr; 5(4):508-12.
    View in: PubMed
    Score: 0.031
  163. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.026
  164. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2004 Aug 15; 20(4):445-50.
    View in: PubMed
    Score: 0.026
  165. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002 Jul; 36(1):227-42.
    View in: PubMed
    Score: 0.022
  166. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.021
  167. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol. 2001 Aug; 33(2):123-6.
    View in: PubMed
    Score: 0.021
  168. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018 08; 69(2):278-285.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.